PDSB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PDS Biotechnology Corp (PDSB) is not a strong buy for a beginner, long-term investor at this time. Despite a pre-market price increase of 13.13%, the lack of significant positive financial performance, no strong trading signals, and neutral trading sentiment suggest that this stock does not align with the user's investment goals.
The stock shows a bullish moving average trend (SMA_5 > SMA_20 > SMA_200), and the MACD histogram is positive but contracting. RSI is neutral at 31.721. Key support and resistance levels are Pivot: 1.171, R1: 1.358, S1: 0.984, R2: 1.474, S2: 0.868. However, the technical indicators do not provide a strong buy signal.
Pre-market price increase of 13.13% and bullish moving averages.
No recent news, no significant hedge fund or insider trading trends, and weak financial performance with declining net income (-4.90% YoY) and EPS (-28.57% YoY). Additionally, no recent congress trading data or analyst ratings are available.
In 2025/Q4, revenue remained at 0 with no YoY growth. Net income dropped to -7,562,919 (-4.90% YoY), and EPS decreased to -0.15 (-28.57% YoY). Gross margin remained at 0 with no growth.
No recent analyst ratings or price target changes are available for PDSB.
